Mafenide
From Wikipedia the free encyclopedia
 | This article needs additional citations for verification. (September 2022) |
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Sulfamylon, Mafylon |
| AHFS/Drugs.com | Monograph |
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.004.843 |
| Chemical and physical data | |
| Formula | C7H10N2O2S |
| Molar mass | 186.23 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Mafenide (INN; usually as mafenide acetate, trade name Sulfamylon) is a sulfonamide-type medication used as an antibiotic. It was approved by the FDA in 1948.[citation needed]
Uses[edit]
Mafenide is used to treat severe burns.[1][2] It is used topically as an adjunctive therapy for second- and third-degree burns. It is bacteriostatic against many gram-positive and gram-negative organisms, including Pseudomonas aeruginosa. Some sources state that mafenide is more appropriate for non-facial burns, while chloramphenicol/prednisolone or bacitracin are more appropriate for facial burns.[3]
Mechanism of action[edit]
Mafenide works by reducing the bacterial population present in the avascular tissues of burns and permits spontaneous healing of deep partial-thickness burns. [citation needed]
Adverse reactions[edit]
Adverse reactions can include superinfection, pain or burning upon application, rash, pruritus, tachypnea, or hyperventilation. Mafenide is metabolized to a carbonic anhydrase inhibitor, which could potentially result in metabolic acidosis.[4]
Drug interactions[edit]
There are no significant interactions.[citation needed]
Contraindications[edit]
Mafenide is contraindicated in those with sulfonamide hypersensitivity or renal impairment.
Dosage[edit]
For use as adjunctive therapy for second- and third-degree burns to prevent infection, adults and children should apply topically to a thickness of approximately 1.6 mm to cleaned and debrided wound once or twice per day with a sterile gloved hand. The burned area should be covered with cream at all times.[citation needed]
References[edit]
- ^ Siuda JF, Cihonski CD (November 1972). "New compounds: carbamate derivatives of mafenide (homosulfanilamide)". Journal of Pharmaceutical Sciences. 61 (11): 1856–1857. doi:10.1002/jps.2600611143. PMID 4652670.
- ^ Haynes BW (June 1971). "Mafenide acetate in burn treatment". The New England Journal of Medicine. 284 (23): 1324. doi:10.1056/NEJM197106102842310. PMID 5576444.
- ^ Haik J, Ashkenazy O, Sinai S, Tessone A, Barda Y, Winkler E, et al. (November 2005). "Burn care standards in Israel: lack of consensus". Burns. 31 (7): 845–849. doi:10.1016/j.burns.2005.04.012. PMID 15967581.
- ^ "Sulfamylon (Mafenide Acetate)". RxList. Retrieved 22 December 2022.